1/17
Vocabulary flashcards covering key concepts, medical terms, and pharmacological agents used in the treatment of myasthenia gravis, Alzheimer disease, and cholinergic disorders.
Acetylcholine
An essential neurotransmitter with high concentrations in the motor cortex and basal ganglia that plays an important role in cognitive functions, gut secretory/motor activity, and urinary bladder contraction or relaxation.
Myasthenia Gravis
A chronic autoimmune neuromuscular disease caused by a defect in the transmission of nerve impulses to muscles, characterized by muscle weakness that increases with activity and improves after rest.
Myasthenic Crisis
A severe complication of myasthenia gravis characterized by respiratory insufficiency, worsening tongue and swallowing muscle weakness, and rarely, respiratory failure.
Ptosis
Drooping of one or both eyelids, presenting as an early symptom of myasthenia gravis.
Diplopia
Blurred or double vision occurring as a symptom of myasthenia gravis.
Dysarthria
Impaired speech, listed as a common clinical symptom of myasthenia gravis.
Pyridostigmine (Mestinon)
An acetylcholinesterase inhibitor that increases acetylcholine at the neuromuscular junction to improve muscle strength; indicated for myasthenia gravis and the reversal of nondepolarizing neuromuscular blockers.
Cholinergic Crisis
An adverse overdose state of acetylcholinesterase inhibitors manifesting as severe weakness, respiratory depression, bradycardia, and bronchospasm.
Alzheimer Disease
The most common form of dementia, pathologically characterized by significant neuron loss, cortical neuron shrinkage, neuritic plaques, and neurofibrillary tangles.
Donepezil (Aricept)
A reversible, indirect-acting cholinergic agent that inhibits acetylcholinesterase to increase acetylcholine in the brain; indicated for mild, moderate, and severe Alzheimer disease dementia.
Memantine (Namenda)
An NMDA receptor antagonist that limits excess glutamate activity damaging neurons, indicated for moderate to severe Alzheimer disease.
Namzaric
A combination medication consisting of memantine and donepezil used in the treatment of moderate to severe Alzheimer disease.
Antiamyloid Antibodies
Monoclonal antibodies, such as lecanemab and donanemab, that bind beta-amyloid and promote clearance of amyloid plaques in patients with confirmed beta-amyloid plaques and mild cognitive impairment or mild dementia.
Amyloid-Related Imaging Abnormalities (ARIA)
An adverse effect associated with antiamyloid antibody therapy manifesting as brain edema or microhemorrhage, requiring monitoring through scheduled MRIs.
Bethanechol (Urecholine)
A direct-acting cholinergic agonist that stimulates muscarinic receptors to cause bladder detrusor contraction without readily crossing the blood–brain barrier, used to treat urinary retention.
Irreversible Anticholinesterase Agents
Highly lipid-soluble toxic compounds, including nerve gases (sarin, tabun, soman) and organophosphates (malathion, parathion), that cross the blood–brain barrier and cause widespread peripheral and central cholinergic overstimulation.
Pralidoxime
A pharmacologic agent administered during irreversible anticholinesterase toxicity to relieve neuromuscular blockade.
Atropine
An antidote kept available to counteract excessive muscarinic effects during cholinergic crises or irreversible anticholinesterase toxicity.